BDNF regulates the expression and distribution of vesicular glutamate transporters in cultured hippocampal neurons by Melo, CV et al.
BDNF Regulates the Expression and Distribution of
Vesicular Glutamate Transporters in Cultured
Hippocampal Neurons
Carlos V. Melo1, Miranda Mele1., Michele Curcio1,2., Diogo Comprido1., Carla G. Silva1,
Carlos B. Duarte1,3*
1CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal, 2Department of Biological and Environmental Science, University of Sannio,
Benevento, Italy, 3Department of Life Sciences, University of Coimbra, Coimbra, Portugal
Abstract
BDNF is a pro-survival protein involved in neuronal development and synaptic plasticity. BDNF strengthens excitatory
synapses and contributes to LTP, presynaptically, through enhancement of glutamate release, and postsynaptically, via
phosphorylation of neurotransmitter receptors, modulation of receptor traffic and activation of the translation machinery.
We examined whether BDNF upregulated vesicular glutamate receptor (VGLUT) 1 and 2 expression, which would partly
account for the increased glutamate release in LTP. Cultured rat hippocampal neurons were incubated with 100 ng/ml
BDNF, for different periods of time, and VGLUT gene and protein expression were assessed by real-time PCR and
immunoblotting, respectively. At DIV7, exogenous application of BDNF rapidly increased VGLUT2 mRNA and protein levels,
in a dose-dependent manner. VGLUT1 expression also increased but only transiently. However, at DIV14, BDNF stably
increased VGLUT1 expression, whilst VGLUT2 levels remained low. Transcription inhibition with actinomycin-D or a-
amanitine, and translation inhibition with emetine or anisomycin, fully blocked BDNF-induced VGLUT upregulation.
Fluorescence microscopy imaging showed that BDNF stimulation upregulates the number, integrated density and intensity
of VGLUT1 and VGLUT2 puncta in neurites of cultured hippocampal neurons (DIV7), indicating that the neurotrophin also
affects the subcellular distribution of the transporter in developing neurons. Increased VGLUT1 somatic signals were also
found 3 h after stimulation with BDNF, further suggesting an increased de novo transcription and translation. BDNF
regulation of VGLUT expression was specifically mediated by BDNF, as no effect was found upon application of IGF-1 or
bFGF, which activate other receptor tyrosine kinases. Moreover, inhibition of TrkB receptors with K252a and PLCc signaling
with U-73122 precluded BDNF-induced VGLUT upregulation. Hippocampal neurons express both isoforms during
embryonic and neonatal development in contrast to adult tissue expressing only VGLUT1. These results suggest that BDNF
regulates VGLUT expression during development and its effect on VGLUT1 may contribute to enhance glutamate release in
LTP.
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Introduction
BDNF (brain-derived neurotrophic factor) is a pro-survival
protein that promotes neuronal differentiation and synaptic
plasticity [1,2], in addition to neuroprotection [3,4]. During
development, BDNF stimulates the formation of appropriate
synaptic connections, controlling the direction and rate of axon
growth [5,6], as well as the shape of dendritic arbors and spines
[7–9]. In the adult hippocampus, BDNF is also involved in
learning [10,11] and memory formation [12,13], and is essential
for long-term potentiation (LTP) [14–18].
The effects of BDNF are mainly mediated through activation of
the TrkB (tropomyosin-related kinase B receptor) receptor tyrosine
kinase as well as the p75 neutrotrophin receptor (p75NTR) [19].
Activation of TrkB receptors by BDNF leads to receptor
dimerization and trans-autophosphorylation of several tyrosine
residues in the intracellular domain, including Y490 and Y816,
which allow recruiting proteins containing PTB and SH2 (Src
homology-type 2) domains, activating in parallel the Ras-ERK
(extracellular signal-regulated kinase), PI3-K (phosphatidylinositol
3-kinase)/Akt and phospholipase C-c (PLCc) signaling pathways
[20]. Trans-autophosphorylation of Y816 recruits and activates
cytoplasmic PLCc, which hydrolyzes PIP2 (phosphatidylinositol
4,5-bisphosphate) into IP3 (inositol 1,4,5-trisphosphate) and DAG
(diacylglycerol). IP3 promotes Ca2+ release from internal stores,
activating [Ca2+]i-regulated enzymes, including Ca
2+- and cal-
modulin-dependent protein kinases (CAMKs), and protein kinase
C (PKC) isoforms [21]. Concomitantly, DAG stimulates DAG-
regulated PKC isoforms, such as PKCd [20]. The PLCc pathway
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is central in LTP [18,22,23] and growth cone guidance [6],
retrograde synaptic modification [24] and dendritic spine mor-
phology [25] regulated by activation of TRPC (transient receptor
potential canonical) channels. Trans-autophosphorylation of Y490
enables recruitment of Shc (Src homology 2-containing protein),
IRS1 (insulin receptor substrate 1) and IRS2 linker proteins,
thereby activating the Ras-ERK and PI3K/Akt cascades [26].
ERK translocates to the nucleus upon phosphorylation, regulating
gene expression through isoform-specific activation of transcrip-
tion factors, including cAMP-response element binding protein
(CREB) (through ERK1/2/5), MEF2 (downstream of ERK5) or
Elk1 (following activation of ERK1/2) [27]. The Ras-ERK
signaling pathway is crucial for neurogenesis [28], inhibition of
proapoptotic proteins [29], stimulation of pro-survival gene
expression [30] and protein synthesis-dependent plasticity [31].
The PI3K/Akt pathway has a pivotal role in cell survival [32],
neuroprotection [3], trafficking of synaptic proteins [33] and can
also directly control protein synthesis through mTOR (mamma-
lian target of rapamycin) activation and 4EBP phosphorylation
[34].
The TrkB-activated signaling pathways account for nearly all
BDNF synaptic effects but their biological responses likely reflect
BDNF or TrkB receptor levels and the spatiotemporal pattern
of BDNF stimulation, especially when activated pre- and/or
postsynaptically [35]. Nevertheless, the molecular mechanisms
underlying BDNF signaling in short-term plasticity and long-
term potentiation are not fully understood. We have previously
reported that BDNF induces significant proteome changes [36],
including the regulation of AMPA and NMDA receptors
involved in molecular mechanisms of synaptic plasticity
[37,38]. BDNF promotes phosphorylation of synapsin I [39]
and beta-catenin [40] increasing synaptic vesicle docking at the
active zone and quantal glutamate release [39,41]. However,
direct presynaptic effectors of protein synthesis-dependent
BDNF signaling on glutamatergic function, which also contrib-
utes to LTP and memory formation [22,23], have not been
identified thus far. The vesicular glutamate transporters
(VGLUT) are such target candidates because they mediate L-
glutamate uptake into synaptic vesicles and are required for
exocytic glutamate release at presynaptic terminals [42].
Moreover, VGLUT1 and VGLUT2 expression is developmen-
tally regulated in order to match vesicle cycling and quantal
amplitude [43,44]. In addition, VGLUT isoforms have similar
substrate specificity, transport activity and kinetics but comple-
mentary expression, which correlates with release probability
and potential for plasticity [45]. Therefore, the current study
aimed at examining the effect of BDNF on the expression of
VGLUT, given their relevance in LTP, learning and memory
function [46,47]. We report that BDNF regulates VGLUT gene
and protein expression during development of cultured hippo-
campal neurons, through activation of the PLCc signaling
pathway, and also affects VGLUT subcellular distribution,
further suggesting a role in BDNF-induced LTP.
Materials and Methods
Ethics Statement
Experiments were performed according to the European Union
Directive 86/609/EEC and the legislation Portaria n. 1005/92,
issued by the Portuguese Government for the protection of
animals used for experimental and other scientific purposes. Dams
were sacrificed by cervical dislocation. Embryos were then
surgically removed and sacrificed by decapitation.
Hippocampal Cultures
Primary cultures of rat hippocampal neurons were prepared
from the hippocampi of E18–E19 Wistar rat embryos, after
treatment with trypsin (0.06%, for 15 min at 37uC; GIBCO-
Invitrogen) and deoxyribonuclease I (5.36 mg/ml), in Ca2+- and
Mg2+-free Hank’s balanced salt solution (HBSS; 5.36 mM KCl,
0.44 mM KH2PO4, 137 mM NaCl, 4.16 mM NaHCO3,
0.34 mM Na2HPO4.2H2O, 5 mM glucose, 1 mM sodium pyru-
vate, 10 mM HEPES and 0.001% phenol red). The hippocampi
were then washed with HBSS containing 10% fetal bovine serum
(GIBCO-Invitrogen), to stop trypsin activity, and transferred to
Neurobasal medium (GIBCO-Invitrogen) supplemented with B27
supplement (1:50 dilution; GIBCO-Invitrogen), 25 mM glutamate,
0.5 mM glutamine and 0.12 mg/ml gentamycin. The cells were
dissociated in this solution and were then plated in 6-well plates
(870,000 cells/well) coated with poly-D-lysine (0.1 mg/ml), or on
poly-D-lysine coated glass coverslips, at a density of 80,000 cells/
well (12-well plates). The cultures were maintained in a humidified
incubator of 5% CO2/95% air, at 37uC, for 7 or 14 days. BDNF
stimulation was carried out by adding BDNF (Regeneron or
PeproTech) in Neurobasal medium to a final concentration of
100 ng/ml, for the indicated period of time. When appropriate,
1.5 mM a-amanitin or actinomycin D (transcription inhibitors),
2.0 mM emetine or anisomycin (translation inhibitors) (Calbio-
chem), 200 nM K252a (TrkB inhibitor), 5 mM U73122 (PLCc
pathway inhibitor), 5 mM chelerythrine (PKC inhibitor) or 1 mM
KN-93 (CAMKII inhibitor), 20 mM PD098059 or 10 mM U0126
(Ras-ERK pathway inhibitors), 30 mM LY294002 or 300 nM
Wortmannin (PI3K/Akt pathway inhibitors) (Sigma-Aldrich
Quı´mica) were added 30 min before BDNF stimulation, as
indicated. The cells were further incubated with the signaling
inhibitors for 3 h or 5 h, during BDNF stimulation. When
appropriate, 100 ng/ml IGF-1 (insulin-like growth factor 1) and
bFGF (basic fibroblast growth factor) (Sigma-Aldrich Quı´mica)
were added in lieu of BDNF.
Preparation of Extracts
Hippocampal neurons (DIV7/DIV14) were washed twice
with ice-cold PBS and once more with PBS supplemented with
1 mM DTT and a cocktail of protease inhibitors (0.1 mM
PMSF; CLAP: 1 mg/ml chymostatin, 1 mg/ml leupeptin, 1 mg/
ml antipain, 1 mg/ml pepstatin; Sigma-Aldrich Quı´mica). The
cells were then lysed with RIPA buffer (150 mM NaCl, 50 mM
Tris-HCl, 5 mM EGTA, 1% Triton, 0.5% DOC and 0.1%
SDS at a final pH 7.5), supplemented with 50 mM NaF,
Figure 1. BDNF upregulates VGLUT1 and VGLUT2 protein expression through a translation-dependent mechanism. (A–B) Cultured
hippocampal neurons at DIV7 (A) and DIV14 (B) were incubated with 100 ng/ml BDNF for different time periods and total VLGUT1 and VGLUT2
protein levels were compared to control (without BDNF) expression, upon normalization with b-actin I levels. (C–D) Cultured hippocampal neurons at
DIV7 were pre-incubated or not with the translation inhibitors emetine or anisomycin (2 mM) for 30 min before BDNF stimulation during 30 min or
3 h and VGLUT1 (C) and VGLUT2 (D) protein levels were compared to control expression. When the effect of translation inhibitors was tested, the cells
were incubated with the compounds during stimulation with BDNF. (A–D) Quantification of 3–5 different experiments, performed in independent
preparations, is presented as mean percentage 6 SEM compared to the control (unstimulated neurons). Statistical significance was determined by
One Way ANOVA followed by Bonferronis multiple comparison test with a confidence interval of 99% (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0053793.g001
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1.5 mM sodium orthovanadate and a cocktail of protease
inhibitors, and sonicated, on ice, using an ultrasonic cell
disrupter microtip (VibraCell, Sonics & Materials, Inc.), with
2 cycles of 10 consecutive 1 s, low-intensity pulses interspaced
by 30 s, in order to fully disrupt membrane structure. After
centrifugation at 16,100 g for 10 min, protein in the superna-
tants was quantified using the bicinchoninic acid (BCA) assay
(Thermo Scientific), and the samples were denaturated with 2x
concentrated denaturating buffer (125 mM Tris, pH 6.8,
100 mM glycine, 4% SDS, 200 mM DTT, 40% glycerol,
3 mM sodium orthovanadate, and 0.01% bromophenol blue),
without denaturation at 95uC for 5 min, which would otherwise
cause loss of vesicular proteins to the insoluble fraction.
Total RNA Isolation and Reverse Transcription for Real-
time PCR
Total RNA from cultured hippocampal neurons was extract-
ed with TRIzol reagent (Invitrogen), according to the manu-
facturer’s instructions. The full content of a 6-well cell cluster
plate, with 870,000 cells/well (DIV7), was collected for each
experimental condition. For first strand cDNA synthesis, 3 mg of
total RNA was reverse-transcribed with avian myeloblastosis
(AMV) reverse transcriptase (Roche Applied Science) using
random primers p(dN)6 (3.2 mg), dNTPs (1 mM each), MgCl2
(25 mM), RNase inhibitor (50 units) and gelatin (0.01 mg/ml) in
reaction buffer (10 mM Tris, 50 mM KCl, pH 8.3), in a total
volume of 40 ml. The reaction was performed at 25uC for
10 min, followed by 60 min at 42uC, for primer annealing to
the RNA template and cDNA synthesis, respectively. The
reverse transcriptase was then denatured during 5 min at 99uC,
and the sample was cooled to 4uC for 5 min and finally stored
at -80uC until further use.
Real-time PCR
Real-Time PCR analysis of gene expression was performed
using the LightCycler System II (Roche Applied Science). The
PCR reactions were performed using LightCycler FastStart DNA
Master SYBR Green I (Roche et al., 1996) in 20 ml capillaries.
The primers used for amplification of genes encoding VGLUT1
and VGLUT2 were, respectively, VGLUT1, forward: 59 TGG
AGT TCC GGC AGG AGG AGT T; VGLUT1, reverse: 59
GTG TGT GTG GTG ACT GGG CGC; VGLUT2, forward: 59
GAA GAA ACG GGG GAC ATC ACT GAG A; VGLUT2,
reverse: 59 GTC TTG CGC ACT TTC TTG CAC AAA T. The
primers used for the amplification of endogenous control gene 18S
ribosomal RNA were those included in the Applied Biosystems
TaqMan Ribosomal RNA Control Reagents Kit. Each primer of a
pair was added to the reaction mixture (10 ml) at a final
concentration of 0.8 mM, with 3 mM MgCl2, in addition to the
‘‘Hot Start’’ LightCycler Fast Start DNA Master SYBR Green I
mix (1x) and 2.0 ml of cDNA sample. Thermal cycling was
initiated with activation of the FastStart TaqDNA polymerase by
denaturation during 10 min at 95uC followed by 45 cycles of a
30 s melting step at 95uC, a 5 s annealing step at 60uC, and a 25 s
elongation step at 72uC. All temperature transition rates used were
at 20uC/s. After amplification for 45 cycles, at least 10 cycles
beyond the beginning of the linear phase of amplification, samples
were subjected to a melting curve analysis according to the
manufacturer’s instructions in order to confirm the absence of
unspecific amplification products and primer-dimers. Samples
containing no template were included as negative controls in all
experiments.
mRNA Quantitative Analysis
The mRNA levels of the constitutively expressed reference gene
encoding 18S ribosomal RNA were used as a control, in all
experiments. The relative changes in the mRNA levels of
glutamate receptor subunits in cultured hippocampal neurons
were determined using the DDCp method. Accordingly, for each
experimental condition (unstimulated neurons and neurons
treated with 100 ng/ml BDNF for 30 min or 3 h) the ‘‘crossing
point’’ (Cp) values given by the LightCycler system II software, for
each target gene, were subtracted by the respective Cp value
determined for the 18S gene from the same sample and condition
(DCp). This allows normalizing changes in target gene expression.
Afterward, the DCp values were subtracted by the respective values
of the control for the target gene giving DDCp. The derivation to
the value of 22(DDCp) sets each control at the unity (or 100%),
because DDCp (control) = 0, and the stimuli conditions used were
set at percentage relative to control.
Immunoblotting
Protein samples were separated by SDS-PAGE, in 12%
polyacrylamide gels, transferred to polyvinylidene (PVDF) mem-
branes (Millipore Corp.), and immunoblotted. Blots were
incubated with primary antibodies (overnight at 4uC), washed
and exposed to alkaline phosphatase (ECF)-conjugated secondary
antibody (1 h at room temperature). Alkaline phosphatase activity
was visualized by enhanced chemifluorescence (ECF) on the Storm
860 Gel and Blot Imaging System (GE Healthcare). The following
primary antibodies were used: anti-VGLUT1 and anti-VGLUT2
(1:1000, Synaptic Systems); anti-b-Tubulin I (1:10000, Sigma-
Aldrich Quı´mica), anti-b-actin I (1:20000, Sigma-Aldrich Quı´-
mica), anti-pERK1/2 (1:1000, Cell Signaling), anti-BDNF
(1:1000, Santa Cruz Biotechnology). Anti-rabbit or anti-mouse
IgG alkaline phosphatase-conjugated secondary antibodies (re-
spectively, 1:20000 and 1:10000, GE Healthcare) were used for
detection.
Immunocytochemistry
For immunocytochemistry, cultured hippocampal neurons were
grown on poly-D-lysine coated glass coverslips, at a density of
80000 cells/well (12-well plates), and were then fixed in PBS
supplemented with 4% paraformaldehyde/4% sucrose, for 15 min
at room temperature. After fixation the cells were washed and
permeabilized with 0.25% Triton X-100 in PBS, for 5 min at 4uC,
washed once in PBS for 5 min, and then blocked with 10% BSA,
for 1 h at room temperature, and stained with specific primary
Figure 2. The effect of BDNF on VGLUT1 and VGLUT2 protein levels is dependent on gene expression. (A–B) Hippocampal neurons
were stimulated with BDNF (100 ng/ml) for the indicated periods of time, in the presence or in the absence of the transcription inhibitors a-amanitin
(1.5 mM) or actinomycin-D (1.5 mM), and VGLUT1 (A) and VGLUT2 (B) protein levels were determined by western blot. (C) The variation of Slc17a7
(VGLUT1) and Slc17a6 (VGLUT2) mRNA levels was assayed by real-time PCR, as described in the methods section. The neurons were stimulated with
100 ng/ml BDNF during 30 minutes (grey) or 3 hours (red). (A–C) Quantification of 4–5 experiments, performed in independent preparations, is
presented as mean percentage6 SEM compared to the control (unstimulated neurons), and normalized to 18S reference gene. Statistical significance
was determined by One Way ANOVA followed by Bonferronis multiple comparison test with a confidence interval of 99% (*p,0.05, **p,0.01,
***p,0.001).
doi:10.1371/journal.pone.0053793.g002
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Figure 3. TrkB receptor inhibition blocks BDNF upregulation of VGLUT1 and VGLUT2. (A–C) Cultured hippocampal neurons at DIV7 (A, B)
and DIV14 (C) were stimulated with BDNF (100 ng/ml), for the indicated periods of time, in the presence or absence of a selective inhibitor of tyrosine
kinase activity, K252a (200 nM), and VGLUT1 (A, C) and VGLUT2 (B) protein levels were determined by western blot. Quantification of the indicated
number of experiments, performed in independent preparations, is presented as mean percentage 6 SEM compared to the control (unstimulated
neurons). (D–F) DIV7 hippocampal neurons were stimulated with IGF-1 or bFGF, for 4 or 20 h, and VGLUT1 (D) and VGLUT2 (E) protein levels were
determined by western blot. Quantification of 4 different experiments, performed in independent preparations, is presented as mean percentage 6
SEM compared to the control. Statistical significance was determined by One Way ANOVA followed by Bonferronis multiple comparison test with a
confidence interval of 99% (*p,0.05, **p,0.01, ***p,0.001). (F) DIV7 hippocampal neurons were stimulated with IGF-1 or bFGF, for 15 or 30 min,
and the levels of ERK1/2 phosphorylation were determined by western blot. The antibody used specifically recognizes the phosphorylated isoforms 1
and 2 of ERK, but not the nonphosphorylated (presumably inactive) proteins.
doi:10.1371/journal.pone.0053793.g003
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Figure 4. Inhibition of the PLCc signaling pathway blocks BDNF-induced upregulation of VGLUT1 and VGLUT2 protein levels. (A–D)
DIV7 cultured hippocampal neurons were stimulated with BDNF (100 ng/ml) for the indicated periods of time, in the presence or absence of U73122
(PLCc inhibitor; 5 mM) (A, B), chelerytrine (PKC inhibitor; 5 mM) or KN-93 (CAMKII inhibitor; 1 mM) (C, D), and VGLUT1 (A, C) and VGLUT2 (B, D) protein
BDNF and VGLUT Expression
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antibodies overnight at 4uC. The following primary antibodies
were used: rabbit anti-VGLUT1 or anti-VGLUT2 (1:1000 and
1:500, respectively; Synaptic Systems) and mouse anti-b-Tubulin I
(1:1000; Sigma-Aldrich Quı´mica). Subsequently, cells were
washed six times and incubated for 1 h at 37uC with the
secondary antibodies (Alexa FluorH 488 goat anti-rabbit and Alexa
FluorH 568 goat anti-mouse, 1:500; Invitrogen). The cells were
washed six times, mounted on glass slides with the Dako mounting
medium and viewed on an Axio Observer 2.1 fluorescence
microscope coupled to an Axiocam HRm digital camera. For each
set of experiments the cell images were acquired using identical
exposure settings. The regions of interest for the quantification
were blindly chosen using the tubulin channel. The images were
analyzed for the number, the integrated density (mean intensity6
puncta area), and the intensity of VGLUT puncta along neurites,
as well as the total immunoreactivity in the soma, using the ImageJ
software (NIH). The quantification was performed after determi-
nation of the threshold and subtraction of the background. The
results of the quantification were normalized for the length of the
region of interest in the case of neurites or for the area in the case
of the soma. At least 12 cells per condition were analyzed for each
preparation.
Statistical Analysis
Data are presented as mean 6 SEM of at least three different
experiments, performed in independent preparations. Statistical
analysis was performed using one-way analysis of variance
(ANOVA) followed by the Dunnett’s or Bonferroni post-tests, at
a 99% confidence interval, or using the Student’s t test, as
indicated in the figure captions.
Results
BDNF Upregulates VGLUT1 and VGLUT2 Total Protein
Levels
7 and 14 DIV cultured hippocampal neurons were incubated
with or without 100 ng/ml BDNF, for different time periods
(30 min to 24 h), in order to determine whether acute stimulation
with BDNF affects the protein expression of vesicular glutamate
transporters. VGLUT1 and VGLUT2 protein levels were
determined by Western blotting (Fig. 1A). At DIV7, BDNF
rapidly and significantly upregulated VGLUT2 protein levels,
while VGLUT1 protein levels were only transiently upregulated at
the initial time points, subsequently returning to levels similar to
the control condition (unstimulated neurons). In contrast, at
DIV14, BDNF did not significantly change VGLUT2 protein
levels but instead upregulated VGLUT1 throughout time (Fig. 1B).
The increase in VGLUT2 protein levels at DIV7 and in VGLUT1
at DIV14 had distinct kinetics, and the maximal effects were found
after incubation with BDNF for 3 h and 24 h, respectively. At
DIV7, after a rapid increase, VGLUT2 protein levels remained
high and relatively similar to the maximal value (3 h), even 24 h
after incubation, while the abundance of VGLUT1 showed a slow
and gradual increase, in comparison to the control. The sustained
increase in VGLUT1 and VGLUT2 protein levels observed in
hippocampal neurons (DIV14 and DIV7, respectively) subjected
to a chronic stimulation with BDNF was not observed when the
incubation was limited to 4 h, and followed by 14 h incubation in
culture conditioned medium (p.0.05) (Fig. S1). The effect of
BDNF on VGLUT2 expression was not further examined at
DIV14 because it was not significant and the endogenous
expression levels of this isoform are rather low and variable, in
developed neurons. These results mimic the developmental switch,
from VGLUT2 to VGLUT1 expression, observed in postnatal
hippocampal neurons [42,43,48].
In order to test whether the effect of BDNF resulted from an
increase in protein synthesis, we used two translation inhibitors,
anisomycin and emetine. Hippocampal neurons were stimulated
with BDNF for 30 min or 3 h, in the presence or absence of
translation inhibitors, which were added to the cultured media
30 min prior to BDNF stimulation and kept in the media during
incubation with BDNF. Emetine (2 mM) or anisomycin (2 mM)
fully abrogated the effect of BDNF on VGLUT1 (Fig. 1C) and
VGLUT2 (Fig. 1D) isoforms at DIV7. None of the protein
synthesis inhibitors reduced VGLUT1 or VGLUT2 protein levels
under control conditions (p.0.05), in agreement with the
relatively long half-life suggested for VGLUT2 [49]. However,
translation inhibition was not tested at DIV14 because BDNF only
upregulates VGLUT1 protein levels for long incubation periods,
above the cellular toxicity threshold of emetine and anisomycin
[50]. Treatment with anisomycin or emetine alone did not alter
VGLUT1 or VGLUT2 protein levels in the time periods tested
(p.0.05). Taken together, these results indicate that BDNF
upregulates VGLUT isoforms 1 and 2 through a protein-synthesis
dependent mechanism, and rule out the hypothesis of a reduction
in protein degradation.
BDNF Upregulates VGLUT1 and VGLUT2 by Enhancing
Transcriptional Activity
BDNF signaling may stimulate gene transcription [51] and/or
protein synthesis [52,53]. Hence, we used two different transcrip-
tion inhibitors, a-amanitin (1.5 mM) and actinomycin D (1.5 mM)
to test the role of transcription in the upregulation of vesicular
glutamate transporters by BDNF. Both transcription inhibitors
blocked the effect of BDNF on VGLUT1 (Fig. 2A) and VGLUT2
(Fig. 2B) protein levels and had no effect on the abundance of
VGLUT variants in the absence of this neurotrophin, relative to
the control condition. In agreement with these findings, real-time
PCR experiments showed that BDNF stimulation for 30 min
caused an approximately 2-fold increased in VGLUT1 mRNA
levels (p,0.001). A significant increase in VGLUT2 mRNA
(approximately 3-fold) was also found when cells were incubated
with the neurotrophin for 3 h (p,0.001), with VGLUT1 mRNA
levels remaining at a similar level to that of stimulation for only
30 min (Fig. 2C). Overall, the results suggest that BDNF regulates
VGLUT1 and VGLUT2 gene expression, likely through activa-
tion of a BDNF signaling-modulated transcription mechanism
and/or transcription factor(s).
VGLUT Upregulation Depends on TrkB Receptor
Activation Specifically Induced by BDNF
BDNF signaling may stimulate gene transcription [51] and/or
protein synthesis [52,53], essentially through activation of TrkB
receptors [33]. K252a is a potent inhibitor of tyrosine protein
kinase activity of TrkA, TrkB and TrkC receptors, blocking
receptor autophosphorylation and, consequently, the biological
levels were determined by western blot. Quantification of the indicated number of experiments, performed in independent preparations, is
presented as mean percentage 6 SEM compared to the control (unstimulated neurons). Statistical significance was determined by One Way ANOVA
followed by Bonferronis multiple comparison test with a confidence interval of 99% (*p,0.05, **p,0.01, ***p,0.001). (E) Schematic representation
of BDNF-induced TrkB receptor trans-activation and downstream PLCc signaling pathway effectors and inhibitors.
doi:10.1371/journal.pone.0053793.g004
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functions of their neurotrophin ligands [54]. In addition to TrkB,
cultures of embryonic day 18 (E18) hippocampal neurons express
TrkC, but not TrkA receptors [55] and BDNF does not bind to
TrkC receptors [56,57]. The results found show that TrkB
receptor activation is required for upregulation of VGLUT1
(DIV7 and DIV14) and VGLUT2 (DIV7) protein levels because
no effect of BDNF was found when the stimulation with the
neurotrophin was performed in the presence of 200 nM K252a
(p.0.05) (Fig. 3A–C). K252a alone did not significantly alter
either VGLUT1 or VGLUT2 protein levels, when compared to
the control condition (without treatment) (p.0.05), which
demonstrates a specific action of BDNF in the upregulation of
VGLUT expression (Fig. 3A–C). In addition, the lack of effect of
K252a on VGLUT2 expression at DIV14 did not result from the
endogenous release of saturating amounts of BDNF, which would
prevent any additional effect by its exogenous application, because
incubation with the Trk receptor inhibitor alone did not decrease
VGLUT2 protein expression below the control levels (Fig. S2).
This further suggests that BDNF signaling may regulate the
developmental switch from VGLUT2 to VGLUT1 expression in
hippocampal neurons.
Cultured hippocampal neurons express receptors for other
trophic factors, including IGF-1 [58,59] and bFGF [60,61],
which activate the same BDNF-induced signaling pathways in
cultured hippocampal neurons. Moreover, IGF-I enhances the
expression of TrkB receptors and the ability of BDNF to induce
ERK1/2 phosphorylation in cerebrocortical neurons [62] while
bFGF rapidly stimulates BDNF expression in the hippocampal
cell line HiB5 [63]. In this context, we tested whether acute
stimulation with IGF-1 or bFGF in lieu of BDNF would affect
the expression levels of VGLUT isoforms, at two different time
points (4 h and 20 h). Either brief or prolonged incubation with
100 ng/ml IGF-1 or bFGF had no effect on VGLUT1 (Fig. 3D)
and VGLUT2 (Fig. 3E) protein levels, at DIV7, when
compared to the control condition (p.0.05). Since exogenously
applied neurotrophic factors are only effective when their
receptors are expressed at the cell surface and free to bind
their ligands, the absence of any effect on VGLUT expression
could have resulted from ligand or receptor inactivity. In order
to exclude this possibility, we tested the levels of ERK1/2
phosphorylation, upon 15 or 30 min of stimulation with IGF-
1 or bFGF. The antibody used specifically recognizes the
phosphorylated isoforms 1 and 2 of ERK, but not the non-
phosphorylated (presumably inactive) proteins. The results show
ERK1/2 phosphorylation after 15 min incubation with both
IGF-1 and bFGF, and the effect of bFGF was still observed
after 30 min of stimulation. These results confirm that the lack
of effect of IGF-1 and bFGF on VGLUT expression was not
due to inactivity of trophic factors or their receptors (Fig. 3F).
Therefore, we may conclude that BDNF upregulates VGLUT1
and VGLUT2 specifically through activation of TrkB receptors
as K252a fully abrogated the effect in cultured hippocampal
neurons at DIV7 (Fig. 3A, B) and DIV14 for VGLUT1
(Fig. 3C).
BDNF Regulates VGLUT Expression through PLCc
Signaling Pathway Activation
The specificity of BDNF signaling through TrkB activation
prompted us to further assess which pathway(s) triggered by TrkB
trans-autophosphorylation was (were) involved in BDNF-mediated
VGLUT upregulation. For this purpose, we used the chemical
inhibitors U73122 (PLCc pathway), PD098059 or U0126 (Ras-
ERK pathway), and LY294002 or Wortmannin (PI3K/Akt
pathway). At DIV7, U73122 fully abrogated BDNF-induced
VGLUT1 (Fig. 4A) and VGLUT2 (Fig. 4B) upregulation
(p.0.05), indicating that this pathway plays a key role in response
to BDNF. Chemical inhibitors chelerythrine and KN-93 selec-
tively and potently block the activation of PKC and CAMKII,
respectively, two kinases that act downstream of PLCc. We have
found that incubation with KN-93 (1 mM) prevented BDNF-
induced VGLUT1 (p.0.05), but not VGLUT2 upregulation
(p,0.05), while chelerythrin (5 mM) blocked VGLUT2 upregula-
tion (p.0.05), but was without effect on VGLUT1 (p,0.05)
(Fig. 4C, D). These results indicate that BDNF regulates VGLUT
1 and 2 expression through signaling mechanisms acting
downstream of PLCc. VGLUT1 transient upregulation at DIV7
is dependent on CAMKII activation whereas VGLUT2 long
lasting upregulation, at the same developmental stage, requires
PKC activation. Blocking the Ras-ERK (Fig. 5A, B) or PI3-K/Akt
(Fig. 5C, D) signaling pathways with PD098059 or U0126 and
LY294002 or Wortmannin, respectively, showed no significant
effect (p.0.05).
BDNF Affects VGLUT Subcellular Distribution
The subcellular distribution of VGLUT1 and VGLUT2 was
assessed by immunocytochemistry in cultured hippocampal
neurons (DIV7) stimulated or not with 100 ng/ml BDNF, for
different time periods, and imaged by fluorescence microscopy.
VGLUT1-positive neuritic (presumably axonal) labeling transient-
ly increased after 30 min - 3 h of incubation with BDNF when
compared with the control (Fig. 6A). Quantification of the
immunofluorescence images showed a BDNF-induced increase
in the number (Fig. 6B), integrated density (mean intensity6
puncta area) (Fig. 6D) and intensity (Fig. 6E) of VGLUT1 puncta
along neurites, as well as an upregulation in the total immuno-
reactivity in the soma (Fig. 6C). A small but non-significant
upregulation of VGLUT1 protein levels was found in the soma, at
an early time point (30 min), before the maximal increase in
VGLUT1 puncta intensity (3 h) (p,0.001). VGLUT2 punctate
labeling was also increased in the neurites of hippocampal neurons
following stimulation with BDNF for 30 min or 6 h (Fig. 7). In this
case, BDNF was also found to increase the number (Fig. 7B),
integrated density (Fig. 7D) and intensity (Fig. 7E) of VGLUT2
puncta in neurites, with maximal effects at 30 min of incubation
with the neurotrophin. However, BDNF was without effect on
total VGLUT2 immunoreactivity in the soma (p.0.05) (Fig. 7C),
in contrast with the results obtained for VGLUT1. Overall, these
imaging results not only provide further support to the biochem-
istry results previously presented but also show that BDNF affects
Figure 5. Inhibition of the PI3-K/Akt and Ras-ERK signaling pathways has no significant effect on BDNF-induced upregulation of
VGLUT1 and VGLUT2 protein levels. (A–D) DIV7 cultured hippocampal neurons were stimulated with BDNF (100 ng/ml), for the indicated
periods of time, in the presence or absence of Ras-ERK pathway inhibitors PD098059 (20 mM) or U0126 (10 mM) (A, B), or PI3K/Akt inhibitors LY294002
(30 mM) or Wortmannin (300 nM) (C, D), and VGLUT1 (A, C) and VGLUT2 (B, D) protein levels were determined by western blot. Quantification of the
indicated number of experiments, performed in independent preparations, is presented as mean percentage 6 SEM compared to the control
(unstimulated neurons). Statistical significance was determined by One Way ANOVA followed by Bonferronis multiple comparison test with a
confidence interval of 99% (*p,0.05, **p,0.01, ***p,0.001). (E) Schematic representation of BDNF-induced TrkB receptor trans-activation and
downstream effectors and inhibitors of the PI3-K/Akt and Ras-ERK signaling pathways.
doi:10.1371/journal.pone.0053793.g005
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the subcellular distribution and trafficking of VGLUT1 and
VGLUT2 in hippocampal neurons.
Discussion
We and others have previously shown direct presynaptic effects
of BDNF, which upregulates K+-evoked [3H] glutamate release
from hippocampal synaptosomes, in a subset of glutamatergic
synapses expressing TrkB receptors on the plasma membrane
[39,64]. In the current study, we have shown that BDNF regulates
VGLUT1 and VGLUT2 gene and protein expression, during
development of cultured hippocampal neurons, specifically
through activation of TrkB receptors and the PLCc signaling
pathway. At DIV7, BDNF-induced transient VGLUT1 upregula-
tion requires the activation of the PLCc downstream effector
CAMKII, whereas VGLUT2 sustained upregulation, at the same
developmental stage, depends on PKC activation. At DIV14,
BDNF upregulates VGLUT1 expression with no significant effect
on VGLUT2 expression, which was endogenously downregulated
during this period, approximately corresponding to the develop-
mental switch from VGLUT2 to VGLUT1 neurons in postnatal
hippocampus [42,43]. The results also indicate that BDNF affects
VGLUT1 and VGLUT2 subcellular distribution, further suggest-
ing a role in BDNF-induced short-term plasticity and LTP. These
findings correlate with the BDNF-induced increase in the number
of docked vesicles at the active zone and quantal glutamate release
observed at hippocampal excitatory synapses [39,41,65].
Effect of BDNF on VGLUT1 and VGLUT2 Gene and Protein
Expression
In this study, we show that BDNF differentially upregulates
VGLUT isoforms 1 and 2 during the development of hippocampal
neurons in a time-dependent manner (Fig. 1A), by a mechanism
sensitive to inhibition of transcription (Fig. 2A–D) and translation
(Fig. 1C, D). The BDNF-induced sustained increase in VGLUT2
protein levels contrasts with the transient upregulation of
VGLUT1 protein levels induced by the neurotrophin. The latter
effects correlate with the transient increase in TrkB signaling
activity observed in hippocampal neurons incubated with BDNF,
which reached a maximum after about 10 min of exposure to the
neurotrophin and decreased to control levels after 24 h of
incubation [3]. These results also indicate that VGLUT1
synthesized in response to BDNF stimulation is degraded within
less than 24 h. The more sustained BDNF-induced increase in
VGLUT2 protein levels suggests that this transporter has a longer
half-life in hippocampal neurons than VGLUT1. Alternatively,
the results may indicate that the TrkB signaling pathway coupled
to the regulation of VGLUT2 expression (which is distinct from
the pathway responsible for VGLUT1 upregulation) may undergo
a slower inactivation after desensitization of the TrkB receptors. In
addition to the effect on VGLUT protein levels reported here,
BDNF was previously shown to upregulate the expression of the
synaptic vesicle proteins synaptophysin, synaptobrevin and
synaptotagmin, but showed no effect on the presynaptic
membrane proteins syntaxin and SNAP-25, or the vesicle-binding
protein synapsin-I, in organotypical cultures of hippocampal
neurons [66]. BDNF overexpression in a Huntington’s disease
mouse model was previously shown to prevent the decrease of
striatal VGLUT1, but that effect most likely resulted from a
neuroprotective mechanism of BDNF, which may have precluded
the loss of glutamatergic synapses [67].
Immunocytochemistry experiments also showed a rapid effect
of BDNF on VGLUT1 protein levels in the soma, which was
followed by an increase in the expression of this protein in
puncta along neurites (presumably axons). These results suggest
that newly synthesized vesicular glutamate transporters are
delivered to neurites within 3 h, being clustered in both new
and pre-existing puncta. BDNF also induced a sustained
increase in the intensity of VGLUT2 puncta in neurites, but
no changes were found in the somatic abundance of the
transporter. This suggests that VGLUT2 synthesized in the
soma following BDNF stimulation may be rapidly delivered to
neurites or, alternatively, VGLUT2 may be produced locally at
the neurites in response to stimulation with the neurotrophin.
Furthermore, the increase noted in the number of VGLUT1/2
puncta and in the number of transporters clustered in these
regions, in BDNF-stimulated hippocampal neurons may result,
at least partly, from a redistribution of vesicles containing the
vesicular transporters already available in neurites.
VGLUT1 and VGLUT2 were initially identified as Na+-
dependent inorganic phosphate transporters BNPI and DNPI
[68–70] in screenings of cDNAs upregulated by NMDA and
growth factors, respectively [53]. However, the characterization
of VGLUT1 [71,72] and VGLUT2 promoters [73] has only
recently been performed, and no transcription factors or
signaling pathways directly modulating the expression of these
genes have been identified thus far, to our knowledge.
Nonetheless, VGLUT1 protein levels show strong diurnal
cycling, which is lost in mice lacking the period gene Period 2
[74]. CAMKII is maximally active during the subjective day, in
contrast to Erk [75], and the CAMKII inhibitor KN-93 was
shown to block Period 2 expression while the MEK inhibitors
PD98059 and U0126 were without effect [76]. In agreement
with these results, we have found that CAMKII inhibition
blocks BDNF-induced upregulation of VGLUT1 (Fig. 4C),
whereas MEK/ERK inhibition had no significant effect
(Fig. 5A). VGLUT1 is also upregulated in cerebrocortical and
hippocampal regions of rat brains upon antidepressant treat-
ment with fluoxetine, paroxetine or desipramine [77], or in
striatal neurons due to intraperitoneal injection of methanphe-
tamine [78]. In turn, VGLUT2 is upregulated in vasopressin
and oxytocin neurons after osmotic stimulation [79] or the
thalamus of schizophrenic patients [80] although, in all cases,
the underlying transcriptional mechanisms are still unknown.
Nevertheless, these results demonstrate that glutamatergic
neurons regulate glutamate release through modulation of
VGLUT expression, which is endogenously regulated in
developing and mature neurons enabling synaptic refinement
and plasticity [44].
Figure 6. Effect of BDNF on the subcellular distribution of VGLUT1 in cultured rat hippocampal neurons. Hippocampal neurons were
stimulated at 7 DIV with BDNF (100 ng/ml) for 30 min, 3 h or 6 h. Neurons were then stained for total VGLUT1 (green) and b-tubulin I (red) (A) (Scale
bar: 10 mm). Arrowheads show the location of VGLUT1 puncta. The acquired fluorescence images were analysed to assess the number (B), integrated
density (mean intensity6puncta area) (D) and intensity (E) of VGLUT1 puncta in neurites, as well as for VGLUT1 immunoreactivity in the soma (C).
Results were normalized for neuritic length (B, D and E) or for soma area (C). The protein localization was visualized using a Zeiss Axio Observer 2.1
fluorescence microscope (63x Objective). Quantitative particle analysis was performed using ImageJ software. Results are shown as mean percentage
of control of at least three independent experiments (n $30 cells per condition). *p,0.05; **p,0.01; ***p,0.001, significantly different in
comparison to the respective control (unpaired Student’s t-test).
doi:10.1371/journal.pone.0053793.g006
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TrkB Activation and PLCc Signaling in BDNF-mediated
Regulation of Glutamatergic Function
We have found that BDNF regulation of VGLUT expression in
developing hippocampal neurons depends specifically on the
activation of TrkB receptors and PLCc signaling (Fig. 4), and
although stimulation with BDNF is also coupled to the activation
of the Ras/ERK and PI3-K signaling pathways in cultured
hippocampal neurons [3] these pathways do not participate in the
regulation of VGLUT1 and VGLUT2 expression. Interestingly,
the effects of BDNF are specific since stimulation of cultured
hippocampal neurons with IGF-1 and bFGF, which also activate
receptor tyrosine kinases, did not affect VGLUT protein levels.
This difference may be due to a distinct location of the receptors in
the cells and/or to a differential coupling to intracellular signaling
mechanisms. In cultured cerebrocortical neurons, TrkB receptors
were found in all major compartments of each neuron (cell bodies,
dendrites, and axons) both before (DIV4) and during the peak of
(DIV10) synapse formation [81].
The role of PLCc signaling in BDNF-induced upregulation of
VGLUT protein levels in cultured hippocampal neurons corre-
lates with its role in the modulation of other components of
glutamatergic synapses by BDNF. BDNF-induced glutamate
release depends on the PLCc pathway [82,83] and ceases
following treatment with a synthetic glucocorticoid (DEX) that
decreases glucocorticoid receptor-TrkB interaction thereby atten-
uating PLCc activation [84]. Likewise, in cultured hippocampal
neurons, BDNF enhances glutamatergic synaptic transmission by
raising the presynaptic intracellular calcium concentration, due to
Ca2+ release from IP3-sensitive stores [85]. Furthermore, in
hippocampal synaptosomes, the effect of BDNF on K+-evoked
[3H] glutamate release correlates with increased PLCc phosphor-
ylation but not ERK or Akt phosphorylation [64]. Additionally,
both the early and late phases of long-term potentiation are
impaired in the CA1 hippocampus region of homozygous mice
with mutant PLCc docking sites at TrkB receptors, as a result of
impaired CAMKIV and CREB phosphorylation, whilst mutation
of Shc docking site, upstream of Ras-Erk and PI3K/Akt, had no
effect on LTP [18]. The effects of BDNF on LTP are likely
mediated by activation of pre- and post-synaptic TrkB receptors
since selectively blocking of pre- or postsynaptic signaling showed
no significant reduction in LTP [22,23]. The current results
showing BDNF-induced differential upregulation of VGLUT1
and VGLUT2, via CAMKII and PKC activation, respectively,
identify VGLUT as potential presynaptic molecular targets of
BDNF contribution to protein-synthesis dependent mechanisms of
synaptic plasticity. This is supported by evidences showing that
inhibition of BDNF signaling impairs LTM [86,87], VGLUT1
deletion results in impaired LTP, learning and memory function
[46,47], and both isoforms are crucial effectors of synaptic
plasticity [42,88].
In addition to the effects on VGLUT protein levels, activation
of TrkB receptors by BDNF has also been shown to enhance
glutamate release in cultured hippocampal neurons by increasing
the frequency of miniature excitatory postsynaptic currents
(mEPSCs) [85,89]. Other authors have also reported that BDNF
enhances presynaptic function by increasing the number of docked
vesicles at the active zone and quantal glutamate release [39,41]
when the postsynaptic neuron is glutamatergic or excitatory but
not when GABAergic or inhibitory [90]. At the postsynaptic level,
BDNF may potentiate excitatory synaptic transmission by
regulating the expression and synaptic delivery of AMPA receptor
subunit GluA1, through activation of PKC and CAMKII [37],
and upregulating the expression of GluN1, GluN2A and GluN2B
NMDA subunits in a transcription-dependent mechanism [38].
CAMKII and PKC, activated downstream of BDNF binding to
TrkB receptors and PLCc stimulation, have a key role in the
potentiation of NMDA receptors by BDNF [91,92]. These
findings support the model whereby BDNF induces LTP through
targeting of both pre- and postsynaptic mechanisms, critical for
synaptic function. We have also found that incubation with BDNF
has no effect on protein markers of GABAergic neurons,
glutamate decarboxylase 65 and 67 (data not shown), further
demonstrating the correlation between BDNF signaling-depen-
dent regulation of neuronal protein levels and function.
In addition to TrkB receptors, BDNF may also bind to p75NTR,
abundantly expressed in the hippocampus during the late
embryonic and early postnatal [93,94] period of developmental
cell death [95,96], although with low affinity [19]. Furthermore,
BDNF binds to truncated TrkB receptors, but their endogenous
expression does not peak until postnatal days 10–15 (P10–15), in
contrast with the full-length (FL) TrkB mRNA, which reaches
adult levels at birth (P0) [97]. Hence, BDNF signaling in
developing hippocampal neurons is essentially dependent on
TrkB.FL receptor activation. This is in accordance with the results
reported here showing that BDNF-induced upregulation of
VGLUT was inhibited by the Trk receptor inhibitor K252a.
VGLUT1 and VGLUT2 may Mediate BDNF-induced
Mechanisms of Synaptic Plasticity
The current study showing a BDNF-induced upregulation of
total VGLUT protein levels in hippocampal neurons, in addition
to an increase in the punctate distribution of the transporters along
neurites, provides further evidence indicating a role of this
neurotrophin on presynaptic potentiation of glutamatergic trans-
mission. The following evidences suggest that BDNF-induced
upregulation in VGLUT clustering in neurites may significantly
potentiate excitatory neurotransmission: 1) VGLUT expression
directly correlates with synaptic strength [43,44] and biogenesis or
recycling of synaptic vesicles [42,98]; 2) VGLUT1 deficient mice
exhibit decreased spontaneous glutamate release and quantal
synaptic transmission due to exocytosis of partially filled vesicles in
hippocampal synapses [43]; 3) VGLUT1 overexpression not only
rescues this phenotype but also enhances AMPA receptor-
mediated evoked EPSCs by increasing glutamate release per
vesicle [44]; 4) loss of VGLUT 1 and 2 causes changes in synaptic
vesicle shape and leads to decreased number of vesicles [42,98]; 5)
VGLUT2 deficiency decreases evoked glutamate release proba-
bility and reduces LTD at hippocampal CA3-CA1 synapses of
Figure 7. Effect of BDNF on the subcellular distribution of VGLUT2 in cultured rat hippocampal neurons. Hippocampal neurons at 7
DIV were stimulated with BDNF (100 ng/ml) for 30 min or 6 h. Neurons were immunolabeled with specific antibodies for total VGLUT2 (green) and b-
tubulin I (red) (A) (Scale bar: 10 mm). Arrowheads show the location of VGLUT2 puncta. The acquired fluorescence images were analysed to assess the
number (B), integrated density (mean intensity6puncta area) (D) and intensity (E) of VGLUT2 puncta in neurites, as well as for VGLUT1
immunoreactivity in the soma (C). Results were normalized for neuritic length (B, D and E) or soma area (C). The protein localization was visualized
using a Zeiss Axio Observer 2.1 fluorescence microscope (63x Objective). Quantitative particle analysis was performed using ImageJ software. Results
are shown as mean percentage of control of at least three independent experiments (n $30 cells per condition). **p,0.01; ***p,0.001, significantly
different in comparison to the respective control (unpaired Student’s t-test).
doi:10.1371/journal.pone.0053793.g007
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young postnatal (P11–P14) mice [99]; 6) even though one
transporter apparently suffices to fill a vesicle [100], enhanced
VGLUT expression may increase the number of transporters per
vesicle, thus, accelerating the rate of vesicle filling or its volume
[101]. Conversely, decreased VGLUT1 expression causes depres-
sive behavior and impaired memory in mice [47], while VGLUT2
heterozygotes show decreased neuropathic pain and defense
responses [98,102]. Hence, differences between transcription and
translation rates or synaptic delivery of VGLUT isoforms,
otherwise quite similar in function, further explain presynaptic
regulation of quantal size.
In conclusion, the results presented herein suggest that BDNF
signaling regulates differentially the gene and protein expression of
VGLUT1 and VGLUT2 in developing and mature hippocampal
neurons. Nevertheless, future in vivo studies as required for
verifying the potential role of BDNF-mediated regulation of
VGLUT expression in hippocampal synaptic mechanisms of
short-term plasticity and long-term potentiation.
Supporting Information
Figure S1 Acute BDNF stimulation does not induce a sustained
increase in VGLUT protein levels after removal of the
neurotrophin. (A–B) Cultured hippocampal neurons at DIV14
(A) and DIV7 (B) were incubated with 100 ng/ml BDNF for 4
hours in Neurobasal medium followed by a 14 h recovery period
in culture conditioned medium. Total VGLUT1 (A) and
VGLUT2 (B) protein levels were compared to control (without
BDNF) expression, upon normalization with b-Tubulin levels.
Quantification of ten different experiments, performed in
independent preparations, is presented as mean percentage
6SEM compared to the control (unstimulated neurons). The
differences obtained are not statistically significant, as determined
by paired Student’s t-test with a confidence interval of 95%.
(TIF)
Figure S2 TrkB receptor inhibition has no effect on VGLUT2
expression. Cultured hippocampal neurons at DIV14 were
incubated with a selective inhibitor of tyrosine protein kinase
activity K252a (200 nM) and VGLUT2 protein levels were
determined by western blot. Quantification of the indicated
number of experiments, performed in independent preparations, is
presented as mean percentage 6SEM compared to the control
(unstimulated neurons). Statistical significance was determined by
paired Student’s t-test with a confidence interval of 95%.
(TIF)
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